Skip to main content
. Author manuscript; available in PMC: 2013 May 6.
Published in final edited form as: Int J Cancer. 2009 Aug 15;125(4):942–951. doi: 10.1002/ijc.24424

Figure 7. Treatment of mice bearing heterotopic pancreatic allografts with weekly gemcitabine and every other day TAT-CTMP results in inhibition of tumor growth compared to no treatment and gemcitabine-only controls.

Figure 7

The murine pancreatic adenocarcinoma cell line, Panc-02, was implanted into the right flank of C57/BL6 mice (2.5 × 105). After 14 days (mean tumor diameter approx 5 mm), treatment was initiated. Tumor bearing mice (n=10 per group) receiving gemcitabine were treated with intraperitoneal injections (1.5 mg/mouse, days 14 and 21). Mice receiving TAT-CTMP Inactive or TAT-CTMP were treated every other day for two weeks by intratumoral injection (0.5 mg/mouse, days 14, 16, 18, 20, 22, 24, 26). Results are expressed as the mean, with bars representing standard error of the mean.